You are here
Home > Drugs > HETLIOZ ® (tasimelteon) capsules

Clinical pharmacology

Initial U.S. Approval:  2014

Mechanism of Action: melatonin receptor agonist

Indications and usage 

INDICATIONS AND USAGE:  HETLIOZ is a melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24)

Dosage and administration 

Drug UPDATES:  HETLIOZ ® (tasimelteon) capsules,
[Drug information  /  PDF]  
Dosing:  Click (+) next to Dosage and Administration section (drug info link)

The recommended dosage of HETLIOZ is 20 mg per day taken before bedtime, at the same time every night.
Because of individual differences in circadian rhythms, drug effect may not occur for weeks or months.
HETLIOZ should be taken without food [see Clinical Pharmacology (12.3)].

How supplied

HOW SUPPLIED: Capsules: 20 mg


HETLIOZ ® (tasimelteon) capsules,
[Drug information  /  PDF]   


National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates.  A local search option of this data can be found here.

HETLIOZ ® (tasimelteon) capsules